Embryo-selection startup Herasight emerged from stealth on 30 July with a peer-reviewed paper describing algorithms that predict the risk of 17 common diseases based on polygenic scores. The company says the models, validated on siblings, outperform existing offerings and maintain their accuracy in families of non-European ancestry. Herasight has already screened hundreds of embryos and is making the service available to prospective parents through in-vitro fertilisation clinics. Besides disease risk, the platform allows customers to rank embryos on complex traits such as height and intelligence, marking the first commercial service to advertise IQ selection. A web-based calculator lets families explore potential outcomes before proceeding. The launch intensifies competition in a nascent market that includes firms such as Nucleus, which Herasight directly challenges in its technical documentation. Population-genetics researcher Joe Pickrell has joined as an adviser, signalling academic interest in the company’s approach even as ethical debates over embryo selection continue.